Management of the 351 responders with pancreatic adenocarcinoma stratified by stage and treatment centre in Ontario, Canada, in 2003–2006
| Management | Stage; treatment hospital; no. (%)* | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage I | Stage II | Stage III | Stage IV | |||||||||
| Academic | Nonacademic | p value | Academic | Nonacademic | p value | Academic | Nonacademic | p value | Academic | Nonacademic | p value | |
| Curative surgery† | 15 (100) | 9 (100) | NA | 83 (100) | 23 (100) | NA | 5 (14) | 12 (52) | 0.001 | 12 (26) | 7 (23) | 0.77 |
| No curative surgery | 0 (0) | 0 (0) | NA | 0 (0) | 0 (0) | NA | 32 (86) | 11 (48) | NA | 35 (74) | 24 (77) | NA |
| Curative surgery completed | 15 (100) | 9 (100) | NA | 83 (100) | 22 (96) | 0.22 | 0 (0) | 0 (0) | NA | 7 (58) | 2 (29) | 0.35 |
| Curative surgery aborted | 0 (0) | 0 (0) | NA | 0 (0) | 1 (4) | NA | 5 (100) | 12 (100) | NA | 5 (42) | 5 (71) | NA |
| Chemotherapy‡ | 3 (20) | 0 (0) | 0.27 | 37 (45) | 5 (22) | 0.05 | 22 (59) | 13 (57) | 0.82 | 24 (51) | 20 (65) | 0.24 |
| No chemotherapy | 12 (80) | 9 (100) | NA | 46 (55) | 18 (78) | NA | 15 (41) | 10 (43) | NA | 23 (49) | 11 (35) | NA |
| Clinical trials | 1 (9) | 0 (0) | 1.0 | 10 (19) | 1 (9) | 0.67 | 2 (8) | 2 (12) | 1.0 | 4 (12) | 2 (9) | 1.0 |
| No clinical trials | 10 (91) | 4 (100) | NA | 43 (81) | 10 (91) | NA | 23 (92) | 15 (88) | NA | 29 (88) | 20 (91) | NA |